Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
[New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 8. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy].
Idiopathic inflammatory demyelinating disorders of the central nervous system in children.
Inter-hemispheric functional connectivity changes with corpus callosum morphology in multiple sclerosis.
Role of the nucleolus in neurodegenerative disease with particular reference to the retina: a review.
A prospective study of "undiagnosed" isolated myelopathy: I. Case selection and clinical features.
Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis.
Hyperinsulinemia in newly diagnosed patients with multiple sclerosis.
Microbial view of central nervous system autoimmunity.
OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology.
A case of IgM paraproteinemic neuropathy associated with anti-sulfated glucuronic paragloboside (SGPG) IgG antibody without anti-myelin-associated glycoprotein (MAG) activity.
Inherited and acquired disorders of myelin: The underlying myelin pathology.
[Effect of therapeutic apheresis on the lymphocyte sensitivity to corticosteroids in patients with secondary progressive multiple sclerosis.]
Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis.
Multiple sclerosis: Daclizumab HYP shows superiority to IFN-β1a for reducing relapses in multiple sclerosis.
Commentary on neuromyelitis optica associated with painful paroxysmal dystonia: case report and literature review.
Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
Lessons learned from studies of natural resistance in murine experimental autoimmune encephalomyelitis.
The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.
Production and use of lentivirus to selectively transduce primary oligodendrocyte precursor cells for in vitro myelination assays.
Multiple sclerosis and mitochondrial gene variations: A review.
A patient's perspective of partnership in the treatment of multiple sclerosis: MS regimes-An orchestrated approach.
Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation.
Retinal layer segmentation of macular OCT images using boundary classification.
Efficacy of Intravenous Immunoglobulin in Neurological Diseases.
Stoppers and non-starters of disease-modifying treatment in multiple sclerosis.
Pages
« first
‹ previous
…
461
462
463
464
465
466
467
468
469
…
next ›
last »